Collaboration
Feb 15, 2026
Bioscibex has secured an Innosuisse project to further automate mammalian cell culture with its SW1NGO bioreactor. In collaboration with HES-SO Valais-Wallis and Hochschule Luzern, the nine-month initiative aims to transform seed train production into a fully automated, single-step process from cell thaw to pilot scale.
Bioscibex advances its mission to automate mammalian cell culture for the biopharma industry with the newly approved Innosuisse project: "Novel automated single-use bioreactor for one-step seed train production: from cell revival to N-stage inoculation in one system."
This nine-month effort refines SW1NGO, the single-use bioreactor-incubator scaling cultures from 30 mL to 30 L without manual passaging—from vial thaw to pilot scale.
Monoclonal antibodies and biologics save lives, yet production starts with slow, manual, error-prone mammalian cell expansion. The project reimagines seed trains as one-step automated workflows—speeding early growth, boosting robustness, cutting costs, and hastening patient access to therapies.
A powerhouse academic duo powers this advance. At HES-SO Valais-Wallis, Prof. Valentin Jossen leads process intensification, automation and lab validation of enhanced SW1NGO in Valais facilities. Hochschule Luzern (HSLU) with Prof. Dr. Ulf Christian Müller deliver 3D modelling and simulation (CFD) for superior bioreactor control and performance.
